Stock analysis searches answered, part 25 of 43

Upland resources limited bullish and bearish analyst opinions

The legal-form ending in “Upland resources limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Upland resources limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Upland resources limited” appears in 5 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “upland” (search terms considered: upland, resources).

In the 5 most relevant full-text hits returned for “Upland resources limited”, filings range from 2025-10-30 to 2026-02-18. The filers whose documents mention it most often are Pelican Holdco, Inc. (CIK 0002093507) (5 hits); Greenland Exploration Ltd (CIK 0002094400) (5 hits); March GL Co (CIK 0002094386) (5 hits); Pelican Acquisition Corp (CIK 0002037431) (5 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 19 entities whose registered name contains the word “upland”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “upland” 19, “resources” 478. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “upland” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Uxin limited bullish and bearish analyst opinions

For “Uxin limited bullish and bearish analyst opinions”, the matching SEC registrant is Uxin Ltd, which trades as UXIN and files under Central Index Key 1729173. EDGAR puts it in the “Services-Business Services, NEC” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-23, across 312 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-30 by Uxin Ltd (CIK 1729173) — source document:

We commenced operations in August 2011 through Youxin Internet (Beijing) Information Technology Co., Ltd., or Youxin Hulian, to conduct used car auctions and other transaction related services. In December 2011, we incorporated Uxin Limited in the Cayman Islands as our offshore holding company to facilitate financing and offshore listing. Shortly following its incorporation, Uxin Limited established a wholly-owned subsidiary in Hong Kong, Uxin Hong Kong Limited. In June 2012, in connection with our Series A financing, Uxin Hong Kong Limited established a wholly-owned subsidiary in China, Youxinpai (Beijing) Information Technology Co., Ltd., referred to as Youxinpai or one of our WFOEs. Youxinpai subsequently established and acquired several wholly-owned subsidiaries, among which are Youhan (Shanghai) Information Technology Co., Ltd., or Youhan, and Baogu Automobile Technology Services (Beijing) Co., Ltd.

Financial trend for Uxin Ltd from annual reports, periods 2023-03-31 to 2025-12-31: revenue went from 2,059,241,000 CNY (2023-03-31) to 3,239,693,000 CNY (2025-12-31), a change of +57.3%; net income (loss) went from -137,157,000 CNY (2023-03-31) to -372,387,000 CNY (2024-03-31), a change of -171.5%; total assets went from 718,647,000 CNY (2023-03-31) to 2,418,755,000 CNY (2025-12-31), a change of +236.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1729173, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Uxin Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Uxin Ltd (CIK 1729173) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 98 8-K or 6-K reports in Uxin Ltd’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-09-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1729173 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2018-02-08. Insider trades for Uxin Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Visionwave holdings, inc. bullish and bearish analyst opinions

For “Visionwave holdings, inc. bullish and bearish analyst opinions”, the matching SEC registrant is VisionWave Holdings, Inc., which trades as VWAV, VWAVW and files under Central Index Key 2038439. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a PRE 14A filed 2026-10-14, across 188 filings on record. This is reference material, not trading advice.

Financial trend for VisionWave Holdings, Inc. from annual reports, periods 2024-09-30 to 2025-09-30: net income (loss) was tagged only for 2025-09-30 at -$6.55 million; total assets went from $13,014 (2024-09-30) to $2.69 million (2025-09-30), a change of +20593.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2038439, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures VisionWave Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VisionWave Holdings, Inc. (CIK 2038439) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2025-12-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 78 8-K or 6-K reports in VisionWave Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 188 recent EDGAR filings, VisionWave Holdings, Inc. most often filed 8-K (78), 3 (12), 4 (10), SCHEDULE 13G (10). A selection from 2026-08-24 to 2026-10-14:

The full record for CIK 2038439 is on the EDGAR company page; the latest 10-K there is dated 2025-12-31 and the oldest filing in the recent index dates from 2024-10-01. Insider trades for VisionWave Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Vivani medical, inc. bullish and bearish analyst opinions

For “Vivani medical, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Vivani Medical, Inc., which trades as VANI and files under Central Index Key 1266806. EDGAR puts it in the “Electromedical & Electrotherapeutic Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was SECOND SIGHT MEDICAL PRODUCTS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 836 filings on record. This is reference material, not trading advice.

Financial trend for Vivani Medical, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$13.89 million (2022-12-31) to -$26.61 million (2025-12-31), a change of -91.6%; total assets went from $51.13 million (2022-12-31) to $39.39 million (2025-12-31), a change of -23.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1266806, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Vivani Medical, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Vivani Medical, Inc. (CIK 1266806) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 232 8-K or 6-K reports in Vivani Medical, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-09-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 836 recent EDGAR filings, Vivani Medical, Inc. most often filed 4 (336), 8-K (232), 10-Q (35), 3 (35). A selection from 2026-07-30 to 2026-10-19:

The full record for CIK 1266806 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2003-10-10. Insider trades for Vivani Medical, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wdi corporation bullish and bearish analyst opinions

What this search refers to. WDI Corporation is a Japanese restaurant operator listed in Tokyo; its statutory reports are on EDINET. Official source: disclosure2.edinet-fsa.go.jp.

No SEC filer could be matched to “Wdi corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Wdi corporation” appears in 18 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “wdi” (search terms considered: wdi, corporation).

In the 18 most relevant full-text hits returned for “Wdi corporation”, filings range from 2006-03-17 to 2026-09-24. The filers whose documents mention it most often are CALIFORNIA PIZZA KITCHEN INC (CIK 0000789356) (9 hits); SEI INSTITUTIONAL INVESTMENTS TRUST (CIK 0000939934) (6 hits); Dimensional ETF Trust (CIK 0001816125) (2 hits); PFM Multi-Manager Series Trust (CIK 0001696729) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 2 entities whose registered name contains the word “wdi”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “wdi” 2, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “wdi” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

West enclave merger corp. bullish and bearish analyst opinions

For “West enclave merger corp. bullish and bearish analyst opinions”, the matching SEC registrant is West Enclave Merger Corp., which trades as WENC, WENC-RI, WENC-UN and files under Central Index Key 2104260. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-08-12, across 31 filings on record. This is reference material, not trading advice.

Financial trend for West Enclave Merger Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$40,398 (2026-03-31) to $509,855 (2026-06-30), a change of +1362.1%; total assets went from $658,947 (2026-03-31) to $117.81 million (2026-06-30), a change of +17778.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2104260, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures West Enclave Merger Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on West Enclave Merger Corp. (CIK 2104260) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for West Enclave Merger Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-04-30.

Current reports. Of the 2 8-K or 6-K reports in West Enclave Merger Corp.’s recent EDGAR index, the 2 listed here run from 2026-05-04 to 2026-05-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 31 recent EDGAR filings, West Enclave Merger Corp. most often filed 4 (8), 3 (6), 10-Q (2), 8-K (2). A selection from 2026-05-06 to 2026-08-12:

The full record for CIK 2104260 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-16. Insider trades for West Enclave Merger Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Westport fuel systems inc. bullish and bearish analyst opinions

For “Westport fuel systems inc. bullish and bearish analyst opinions”, the matching SEC registrant is AETHERION TECHNOLOGIES INC., which trades as AETR, WPRT and files under Central Index Key 1370416. EDGAR puts it in the “Engines & Turbines” industry code with Alberta, Canada as its state or country of incorporation; its earlier registered name was WESTPORT FUEL SYSTEMS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 424B3 filed 2026-10-16, across 863 filings on record. This is reference material, not trading advice.

Financial trend for AETHERION TECHNOLOGIES INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$32.70 million (2022-12-31) to -$61.63 million (2025-12-31), a change of -88.5%; total assets went from $407.45 million (2022-12-31) to $94.01 million (2025-12-31), a change of -76.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1370416, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AETHERION TECHNOLOGIES INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AETHERION TECHNOLOGIES INC. (CIK 1370416) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 598 8-K or 6-K reports in AETHERION TECHNOLOGIES INC.’s recent EDGAR index, the 4 listed here run from 2026-09-15 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 863 recent EDGAR filings, AETHERION TECHNOLOGIES INC. most often filed 6-K (598), 4 (32), CORRESP (21), UPLOAD (20). A selection from 2026-09-25 to 2026-10-16:

The full record for CIK 1370416 is on the EDGAR company page; the latest 20-F there is dated 2026-04-23 and the oldest filing in the recent index dates from 2006-06-27. Insider trades for AETHERION TECHNOLOGIES INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Whitehorse finance, inc. bullish and bearish analyst opinions

For “Whitehorse finance, inc. bullish and bearish analyst opinions”, the matching SEC registrant is WhiteHorse Finance, Inc., which trades as WHF, WHFCL and files under Central Index Key 1552198. EDGAR puts it in the “no SIC description” industry code with DE as its state or country of incorporation; its earlier registered name was WhiteHorse Finance, LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K/A filed 2026-10-14, across 625 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by WhiteHorse Finance, Inc. (CIK 1552198) — source document:

We are an externally managed, non-diversified, closed-end management investment company that has elected to be treated as a business development company under the Investment Company Act of 1940, as amended, or the 1940 Act. In addition, for tax purposes, we have elected to be treated as a regulated investment company, or RIC, under Subchapter M of the Internal Revenue Code of 1986, as amended, or the Code, and intend to qualify annually for such treatment. We are a direct lender targeting debt investments in privately held, lower middle market companies located in the United States. We define the lower middle market as those companies with enterprise values between $50 million and $350 million.

Financial trend for WhiteHorse Finance, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $15.68 million (2022-12-31) to $14.34 million (2025-12-31), a change of -8.6%; total assets went from $796.47 million (2022-12-31) to $615.13 million (2025-12-31), a change of -22.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1552198, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures WhiteHorse Finance, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on WhiteHorse Finance, Inc. (CIK 1552198) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 220 8-K or 6-K reports in WhiteHorse Finance, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-04 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1552198 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2012-09-07. Insider trades for WhiteHorse Finance, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Willamette valley vineyards, inc. bullish and bearish analyst opinions

For “Willamette valley vineyards, inc. bullish and bearish analyst opinions”, the matching SEC registrant is WILLAMETTE VALLEY VINEYARDS INC, which trades as WVVI, WVVIP and files under Central Index Key 838875. EDGAR puts it in the “Beverages” industry code with OR as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 586 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-24 by WILLAMETTE VALLEY VINEYARDS INC (CIK 838875) — source document:

The grapes are harvested, fermented and made into wine primarily at the Company’s winery in Turner, Oregon (the “Estate Winery” or “Winery”) and the wines are sold principally under the Company’s Willamette Valley Vineyards label, but also under the Domaine Willamette, Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, Pere Ami and Elton labels. The Company also owns the Tualatin Estate Vineyards and Winery, located near Forest Grove, Oregon (the “Tualatin Winery”). Segments – The Company has identified two operating segments: direct sales and distributor sales, based upon their different distribution channels, margins and selling strategies. Direct sales include retail sales in our tasting rooms, wine club sales, online sales, on-site events, kitchen and catering sales and other sales made directly to the consumer without the use of an intermediary.

Financial trend for WILLAMETTE VALLEY VINEYARDS INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $33.93 million (2022-12-31) to $37.20 million (2025-12-31), a change of +9.6%; net income (loss) went from -$646,492 (2022-12-31) to -$917,685 (2025-12-31), a change of -41.9%; total assets went from $98.68 million (2022-12-31) to $107.74 million (2025-12-31), a change of +9.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 838875, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures WILLAMETTE VALLEY VINEYARDS INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on WILLAMETTE VALLEY VINEYARDS INC (CIK 838875) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2008-08-15, and the most recent 10-K annual report was filed 2026-03-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 62 8-K or 6-K reports in WILLAMETTE VALLEY VINEYARDS INC’s recent EDGAR index, the 4 listed here run from 2026-02-17 to 2026-07-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 838875 is on the EDGAR company page; the latest 10-K there is dated 2026-03-24 and the oldest filing in the recent index dates from 1996-06-07. Insider trades for WILLAMETTE VALLEY VINEYARDS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Worksport ltd. bullish and bearish analyst opinions

For “Worksport ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Worksport Ltd, which trades as WKSP and files under Central Index Key 1096275. EDGAR puts it in the “Motor Vehicle Parts & Accessories” industry code with NV as its state or country of incorporation; its earlier registered name was Worksport Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-10-13, across 629 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Worksport Ltd (CIK 1096275) — source document:

Worksport Ltd., through its subsidiaries, designs, develops, and manufactures innovative products for various markets including automotive accessories, consumer electronics, and both residential and commercial HVAC system markets. Worksport is able to monetize and protect its products through a large and growing intellectual property (“IP”) portfolio with patents, designs, and trademarks relating to, among other things, tonneau covers and components, solar integrated tonneau covers, portable power stations, NP (non-parasitic) hydrogen-based green energy systems, residential heating and cooling systems (heat pumps), and electric vehicle-charging stations. Worksport seeks to provide consumers with next-generation automotive accessories through the production of our innovative line of tonneau covers for light trucks while capitalizing on growing consumer interest in clean energy solutions and power grid independence through the launch of its forthcoming solar tonneau cover (Worksport SOLIS) and mobile battery generator system (Worksport COR).

Financial trend for Worksport Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.53 million (2023-12-31) to $16.10 million (2025-12-31), a change of +952.7%; net income (loss) went from -$12.53 million (2022-12-31) to -$16.16 million (2024-12-31), a change of -29.0%; total assets went from $32.76 million (2022-12-31) to $30.71 million (2025-12-31), a change of -6.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1096275, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Worksport Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Worksport Ltd (CIK 1096275) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-05-16, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 222 8-K or 6-K reports in Worksport Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-26 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1096275 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 1999-10-13. Insider trades for Worksport Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Xflh capital corporation bullish and bearish analyst opinions

For “Xflh capital corporation bullish and bearish analyst opinions”, the matching SEC registrant is XFLH Capital Corp, which trades as XFLH, XFLH-RI, XFLH-UN and files under Central Index Key 2088103. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-06, across 33 filings on record. This is reference material, not trading advice.

Financial trend for XFLH Capital Corp from quarterly and annual reports (three-month periods), periods 2025-11-30 to 2026-05-31: net income (loss) went from -$42,374 (2025-11-30) to $757,749 (2026-05-31), a change of +1888.2%; total assets went from $100.71 million (2026-02-28) to $101.41 million (2026-05-31), a change of +0.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2088103, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures XFLH Capital Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on XFLH Capital Corp (CIK 2088103) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 4 8-K or 6-K reports in XFLH Capital Corp’s recent EDGAR index, the 4 listed here run from 2026-02-17 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 33 recent EDGAR filings, XFLH Capital Corp most often filed 3 (6), SCHEDULE 13G (5), S-1/A (5), 8-K (4). A selection from 2026-04-14 to 2026-10-06:

The full record for CIK 2088103 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-09-29. Insider trades for XFLH Capital Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Yhn acquisition i limited bullish and bearish analyst opinions

For “Yhn acquisition i limited bullish and bearish analyst opinions”, the matching SEC registrant is YHN Acquisition I Ltd, which trades as YHNA, YHNAR, YHNAU and files under Central Index Key 2020987. EDGAR puts it in the “Blank Checks” industry code with Virgin Islands, British as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-08, across 92 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by YHN Acquisition I Ltd (CIK 2020987) — source document:

We are a newly incorporated blank check company formed in the British Virgin Islands as a business company with limited liability (meaning that our public shareholders have no liability, as shareholders of our company, for the liabilities of our company over and above the amount paid for their shares). We were formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to as a “target business.” We are based in Hong Kong. Our principal office is located in Hong Kong and our sponsor and a majority of our executive officers and directors are based in or have significant ties to the mainland China and/or Hong Kong.

Financial trend for YHN Acquisition I Ltd from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from $502,638 (2024-12-31) to $1.33 million (2025-12-31), a change of +163.6%; total assets went from $61.81 million (2024-12-31) to $27.20 million (2025-12-31), a change of -56.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2020987, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures YHN Acquisition I Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on YHN Acquisition I Ltd (CIK 2020987) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for YHN Acquisition I Ltd — registration statements, prospectuses and merger proxies — are filed on EDGAR; 7 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2025-04-04.

Current reports. Of the 18 8-K or 6-K reports in YHN Acquisition I Ltd’s recent EDGAR index, the 4 listed here run from 2026-04-20 to 2026-09-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2020987 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2024-05-10. Insider trades for YHN Acquisition I Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zedge, inc. bullish and bearish analyst opinions

For “Zedge, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Zedge, Inc., which trades as ZDGE and files under Central Index Key 1667313. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 400 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-10-28 by Zedge, Inc. (CIK 1667313) — source document:

Zedge builds digital marketplaces and friendly competitive games around content that people use to express themselves. Our leading products include Zedge Ringtones and Wallpapers, which we refer to as our “Zedge App,” a freemium digital content marketplace offering mobile phone wallpapers, video wallpapers, ringtones, and notification sounds as well as pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, the #1 trusted source for ‘all things emoji’. Our vision is to enable and connect creators who enjoy friendly competitions with a community of prospective consumers in order to drive commerce. We are part of the ‘Creator Economy,’ which is estimated to be worth between $191 billion and $250 billion globally in 2025, with some forecasts placing the global market size as high as $848 billion by 2032 123 . According to multiple reports, there are now over 207 million active content creators worldwide. 45 Furthermore, between 45% and 47% of creators identify as working full-time in this space 678 .

Financial trend for Zedge, Inc. from annual reports, periods 2022-07-31 to 2025-07-31: revenue went from $26.55 million (2022-07-31) to $29.40 million (2025-07-31), a change of +10.7%; net income (loss) went from $9.71 million (2022-07-31) to -$2.39 million (2025-07-31), a change of -124.6%; total assets went from $54.63 million (2022-07-31) to $35.65 million (2025-07-31), a change of -34.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1667313, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Zedge, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Zedge, Inc. (CIK 1667313) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-06-11, and the most recent 10-K annual report was filed 2025-10-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 96 8-K or 6-K reports in Zedge, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-10 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1667313 is on the EDGAR company page; the latest 10-K there is dated 2025-10-28 and the oldest filing in the recent index dates from 2016-03-08. Insider trades for Zedge, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zentalis pharmaceuticals, inc. bullish and bearish analyst opinions

For “Zentalis pharmaceuticals, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Zentalis Pharmaceuticals, Inc., which trades as ZNTL and files under Central Index Key 1725160. EDGAR puts it in the “Pharmaceutical Preparations” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Zentalis Pharmaceuticals, LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-01, across 545 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Zentalis Pharmaceuticals, Inc. (CIK 1725160) — source document:

We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC. We exclusively in-license or solely own worldwide development and commercialization rights to azenosertib.

Financial trend for Zentalis Pharmaceuticals, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2022-12-31) to $0 (2025-12-31); net income (loss) went from -$236.81 million (2022-12-31) to -$137.06 million (2025-12-31), a change of +42.1%; total assets went from $539.31 million (2022-12-31) to $288.97 million (2025-12-31), a change of -46.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1725160, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Zentalis Pharmaceuticals, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Zentalis Pharmaceuticals, Inc. (CIK 1725160) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 89 8-K or 6-K reports in Zentalis Pharmaceuticals, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-27 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1725160 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2017-12-19. Insider trades for Zentalis Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zjk industrial co., ltd. bullish and bearish analyst opinions

For “Zjk industrial co., ltd. bullish and bearish analyst opinions”, the matching SEC registrant is ZJK Industrial Co., Ltd., which trades as ZJK and files under Central Index Key 1941506. EDGAR puts it in the “Bolts, Nuts, Screws, Rivets & Washers” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-19, across 72 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-29 by ZJK Industrial Co., Ltd. (CIK 1941506) — source document:

We are an exempted company incorporated with limited liability under the laws of the Cayman Islands on May 11, 2022 with operations conducted through primarily our Operating Entities, Zhongjinke Shenzhen, Zhongke Components, Zhongjinke Nanjing, PSM-ZJK and Precision Vietnam. In October 2024, we completed our initial public offering and listed our Ordinary Shares on the Nasdaq Capital Market under the symbol “ZJK.” We raised approximately US$6.91 million in gross proceeds from the issuance of new shares from the initial public offering (“IPO”) and partial exercise of over-allotment option prior to deducting underwriting discounts, commissions and expenses. In March 2026, we underwent a share capital reorganization to implement a dual-class share structure.

Financial trend for ZJK Industrial Co., Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $24.79 million (2022-12-31) to $56.10 million (2025-12-31), a change of +126.3%; net income (loss) went from $7.28 million (2022-12-31) to $10.15 million (2025-12-31), a change of +39.5%; total assets went from $38.28 million (2023-12-31) to $79.53 million (2025-12-31), a change of +107.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1941506, tags Assets, ProfitLoss, Revenues; 4 periods shown, dashes mark figures ZJK Industrial Co., Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ZJK Industrial Co., Ltd. (CIK 1941506) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 27 8-K or 6-K reports in ZJK Industrial Co., Ltd.’s recent EDGAR index, the 4 listed here run from 2026-03-06 to 2026-09-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1941506 is on the EDGAR company page; the latest 20-F there is dated 2026-04-29 and the oldest filing in the recent index dates from 2023-09-26. Insider trades for ZJK Industrial Co., Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zooz strategy ltd. bullish and bearish analyst opinions

For “Zooz strategy ltd. bullish and bearish analyst opinions”, the matching SEC registrant is ZOOZ Strategy Ltd., which trades as ZOOZ, ZOOZW and files under Central Index Key 1992818. EDGAR puts it in the “Misc Industrial & Commercial Machinery & Equipment” industry code with Israel as its state or country of incorporation; its earlier registered name was ZOOZ Power Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-08-31, across 144 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-27 by ZOOZ Strategy Ltd. (CIK 1992818) — source document:

Operating and Financial Review and Prospects. 78 Item 6. Directors, Senior Management and Employees 101 Item 7. Major Shareholders and Related Party Transactions. 125 Item 8. Financial Information. 130 Item 9. The Offer and Listing. 130 Item 10. Additional Information. 131 Item 11. Quantitative and Qualitative Disclosures about Market Risk 144 Item 12. Description of Securities Other than Equity Securities. 145 PART II Item 13. Defaults, Dividend Arrearages and Delinquencies. 146 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds. 146 Item 15. Controls and Procedures. 146 Item 16A. Audit Committee Financial Expert. 148 Item 16B. Code of Ethics. 148 Item 16C. Principal Accountant Fees and Services 149 Item 16D. Exemption From the Listing Standards for Audit Committees 149 Item 16E. Purchases of Equity Securities By the Issuer and Affiliated Purchasers 149 Item 16F. Change in Registrant’s Certifying Accountant 149 Item 16G. Corporate Governance 150 Item 16H. Mine Safety Disclosure 150 Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 150 Item 16J. Insider Trading Policies 150 Item 16K. Cybersecurity 150 PART III Item 17.

Financial trend for ZOOZ Strategy Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $764,000 (2023-12-31) to $247,000 (2025-12-31), a change of -67.7%; net income (loss) went from -$7.83 million (2022-12-31) to -$55.59 million (2025-12-31), a change of -610.4%; total assets went from $25.43 million (2022-12-31) to $122.56 million (2025-12-31), a change of +381.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1992818, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ZOOZ Strategy Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ZOOZ Strategy Ltd. (CIK 1992818) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 60 8-K or 6-K reports in ZOOZ Strategy Ltd.’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-08-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1992818 is on the EDGAR company page; the latest 20-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2023-09-18. Insider trades for ZOOZ Strategy Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Acon holding inc. bullish and bearish analyst opinions

What this search refers to. Acon Holding Inc. is a Taiwan-style company name; Taiwanese issuers report through MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Acon holding inc. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Acon holding inc.” appears in 2646+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “acon” (search terms considered: acon, holding).

In the 100 most relevant full-text hits returned for “Acon holding inc.”, filings range from 2018-03-29 to 2026-09-24. The filers whose documents mention it most often are AMERICAN CENTURY ETF TRUST (CIK 0001710607) (61 hits); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (24 hits); Dimensional ETF Trust (CIK 0001816125) (7 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (5 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 49 entities whose registered name contains the word “acon”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “acon” 49, “holding” 487. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “acon” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Acon optics communications inc. bullish and bearish analyst opinions

What this search refers to. Acon Optics Communications Inc. is a Taiwanese optical-component maker name; Taiwan-traded companies file on MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Acon optics communications inc. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Acon optics communications inc.” appears in 19 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “acon” (search terms considered: acon, optics, communications).

A broader EDGAR full-text search for the shorter phrase “Acon optics communications” finds 19 filing documents; among the top 19, the filers mentioning it most are AMERICAN CENTURY ETF TRUST (CIK 0001710607) (10); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (4); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (3). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 19 most relevant full-text hits returned for “Acon optics communications inc.”, filings range from 2023-08-28 to 2026-08-26. The filers whose documents mention it most often are AMERICAN CENTURY ETF TRUST (CIK 0001710607) (10 hits); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (4 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (3 hits); Dimensional ETF Trust (CIK 0001816125) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “acon” 49, “optics” 78, “communications” 467. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

Acr vs noem

What this search refers to. “ACR vs NOEM” compares two terms that are not issuer names — likely acronyms from a technical or medical context — so there is no SEC filer to match. Corporate-registry check: OpenCorporates search for “Acr vs noem”.

No SEC filer could be matched to “Acr vs noem” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Acr vs noem”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “acr” (search terms considered: acr, noem).

Even the shorter phrase “Acr noem” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (acr, noem) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 23 entities whose registered name contains the word “acr”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “acr” 23, “noem” 0. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “acr”: A-ACR-21-FUND, A SERIES OF ANGELLIST-WIAL-FUNDS, LLC (CIK 1652190), ACR ALPINE CAPITAL GP, LLC (CIK 2051667), ACR ALPINE CAPITAL RESEARCH, LLC (CIK 1508822). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “acr” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Adagene

For “Adagene”, the matching SEC registrant is Adagene Inc., which trades as ADAG and files under Central Index Key 1818838. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 191 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-01 by Adagene Inc. (CIK 1818838) — source document:

In December 2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding company. We are a holding company and do not directly conduct any substantive business operations in the PRC. In addition to our R&D activities in the United States, Australia and Singapore, we currently focus our business operations within the PRC through Adagene Suzhou. We (Adagene Inc.), however, hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. Upon the initial public offering, all of our then issued and outstanding preferred shares were automatically converted into ordinary shares on a one-for-one basis.

Financial trend for Adagene Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $9.29 million (2022-12-31) to $7.67 million (2025-12-31), a change of -17.5%; net income (loss) went from -$79.97 million (2022-12-31) to -$17.61 million (2025-12-31), a change of +78.0%; total assets went from $152.40 million (2022-12-31) to $78.26 million (2025-12-31), a change of -48.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1818838, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Adagene Inc. did not tag for that period.

Adagene Inc. has 191 filings in its recent EDGAR index, including 6 annual reports and 0 quarterly reports; its newest filing is a 4 from 2026-10-02.

Current reports. Of the 68 8-K or 6-K reports in Adagene Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-09 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1818838 is on the EDGAR company page; the latest 20-F there is dated 2026-04-01 and the oldest filing in the recent index dates from 2020-09-22. Insider trades for Adagene Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Advanced drainage systems wms latest news october 2026

For “Advanced drainage systems wms latest news october 2026”, the matching SEC registrant is ADVANCED DRAINAGE SYSTEMS, INC., which trades as WMS and files under Central Index Key 1604028. EDGAR puts it in the “Plastics Foam Products” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-05, across 1004 filings on record. This is reference material, not trading advice.

Financial trend for ADVANCED DRAINAGE SYSTEMS, INC. from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $3.07 billion (2023-03-31) to $3.05 billion (2026-03-31), a change of -0.7%; net income (loss) went from $507.09 million (2023-03-31) to $426.46 million (2026-03-31), a change of -15.9%; total assets went from $2.90 billion (2023-03-31) to $4.51 billion (2026-03-31), a change of +55.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1604028, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ADVANCED DRAINAGE SYSTEMS, INC. did not tag for that period.

For the latest news, the fastest official source is the filing feed: ADVANCED DRAINAGE SYSTEMS, INC. (CIK 1604028) filed 166 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-05, and its overall latest filing is a 8-K dated 2026-10-05. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 166 8-K or 6-K reports in ADVANCED DRAINAGE SYSTEMS, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1004 recent EDGAR filings, ADVANCED DRAINAGE SYSTEMS, INC. most often filed 4 (552), 8-K (166), SC 13G/A (44), 3 (38). A selection from 2026-08-06 to 2026-09-16:

The full record for CIK 1604028 is on the EDGAR company page; the latest 10-K there is dated 2026-05-21 and the oldest filing in the recent index dates from 2014-07-24. Insider trades for ADVANCED DRAINAGE SYSTEMS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aecom canyon partners

A query naming engineering firm AECOM with Canyon Partners, a private investment firm that is not an SEC-reporting company.

For “Aecom canyon partners”, the matching SEC registrant is AECOM, which trades as ACM and files under Central Index Key 868857. EDGAR puts it in the “Services-Engineering Services” industry code with DE as its state or country of incorporation; its earlier registered name was AECOM TECHNOLOGY CORP. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-10-08, across 1001 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-11-19 by AECOM (CIK 868857) — source document:

In this report, we use the terms “the Company,” “we,” “us” and “our” to refer to AECOM and its consolidated subsidiaries. Unless otherwise noted, references to years are for fiscal years. Our fiscal year consists of 52 or 53 weeks, ending on the Friday closest to September 30. For clarity of presentation, we present all periods as if the year ended on September 30. We refer to the fiscal year ended September 30, 2024 as “fiscal 2024” and the fiscal year ended September 30, 2025 as “fiscal 2025.” Overview We are a leading global provider of professional infrastructure consulting and advisory services for governments, businesses and organizations throughout the world.

Financial trend for AECOM from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $13.15 billion (2022-09-30) to $16.14 billion (2025-09-30), a change of +22.8%; net income (loss) went from $310.61 million (2022-09-30) to $561.77 million (2025-09-30), a change of +80.9%; total assets went from $11.14 billion (2022-09-30) to $12.20 billion (2025-09-30), a change of +9.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 868857, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures AECOM did not tag for that period.

AECOM has 1001 filings in its recent EDGAR index, including 13 annual reports and 41 quarterly reports; its newest filing is a 3 from 2026-10-08.

Current reports. Of the 173 8-K or 6-K reports in AECOM’s recent EDGAR index, the 4 listed here run from 2026-06-11 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 868857 is on the EDGAR company page; the latest 10-K there is dated 2025-11-19 and the oldest filing in the recent index dates from 2013-04-03. Insider trades for AECOM appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Agape atp corporation bullish and bearish analyst opinions

For “Agape atp corporation bullish and bearish analyst opinions”, the matching SEC registrant is Agape ATP Corp, which trades as ATPC and files under Central Index Key 1713210. EDGAR puts it in the “Services-Health Services” industry code with NV as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-14, across 168 filings on record. This is reference material, not trading advice.

Financial trend for Agape ATP Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.86 million (2022-12-31) to $1.52 million (2025-12-31), a change of -17.9%; net income (loss) went from -$1.69 million (2022-12-31) to -$2.28 million (2025-12-31), a change of -35.1%; total assets went from $2.79 million (2022-12-31) to $24.59 million (2025-12-31), a change of +780.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1713210, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Agape ATP Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Agape ATP Corp (CIK 1713210) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 51 8-K or 6-K reports in Agape ATP Corp’s recent EDGAR index, the 4 listed here run from 2026-02-05 to 2026-03-12, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 168 recent EDGAR filings, Agape ATP Corp most often filed 8-K (51), 10-Q (27), S-1/A (13), CORRESP (13). A selection from 2026-05-15 to 2026-08-14:

The full record for CIK 1713210 is on the EDGAR company page; the latest 10-K there is dated 2026-04-13 and the oldest filing in the recent index dates from 2017-08-24. Insider trades for Agape ATP Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aios tech inc. bullish and bearish analyst opinions

For “Aios tech inc. bullish and bearish analyst opinions”, the matching SEC registrant is AIOS Tech Inc., which trades as AIOS and files under Central Index Key 1603993. EDGAR puts it in the “Services-Computer Integrated Systems Design” industry code with Virgin Islands, British as its state or country of incorporation; its earlier registered name was Nisun International Enterprise Development Group Co., Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-19, across 232 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-20 by AIOS Tech Inc. (CIK 1603993) — source document:

AIOS TECH INC., formerly Hebron Technology Co., Ltd. or Nisun International Enterprise Development Group Co., Ltd (“AIOS Tech” or the “Company”) is now a technology-driven enterprise providing comprehensive financing solutions to SMEs and information technology services. The Company was established under the laws of the British Virgin Islands (“BVI”) on May 29, 2012 as a company limited by shares. Prior to its strategic restructuring in late 2025, the Company was a holding company and conducted its business through its subsidiaries, variable interest entities (“VIEs”) and subsidiaries of VIEs in the People’s Republic of China (“PRC”). Following the divestiture of its legacy businesses and the termination of the VIE structure in December 2025, the Company currently conducts its information technology services through its Hong Kong-based subsidiary, YD Network Technology Company Limited, and directly engages in SME financing solutions in overseas markets (outside mainland China) through the parent company.

Financial trend for AIOS Tech Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $234.17 million (2022-12-31) to $5.07 million (2025-12-31), a change of -97.8%; net income (loss) went from $17.62 million (2022-12-31) to -$220.91 million (2025-12-31), a change of -1353.7%; total assets went from $283.42 million (2022-12-31) to $5.10 million (2025-12-31), a change of -98.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1603993, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AIOS Tech Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AIOS Tech Inc. (CIK 1603993) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 140 8-K or 6-K reports in AIOS Tech Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-26 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1603993 is on the EDGAR company page; the latest 20-F there is dated 2026-04-20 and the oldest filing in the recent index dates from 2014-03-31. Insider trades for AIOS Tech Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aldeyra therapeutics form 4 october 2026 sec

For “Aldeyra therapeutics form 4 october 2026 sec”, the matching SEC registrant is Aldeyra Therapeutics, Inc., which trades as ALDX and files under Central Index Key 1341235. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Aldexa Therapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-29, across 646 filings on record. This is reference material, not trading advice.

Updated Oct 25, 2026 ET

Aluminium market news data centre grid bess renewable energy demand

What this search refers to. This is a commodity-market topic: aluminium demand from data centres, grid build-out and battery storage (BESS). Market data for aluminium is published by the London Metal Exchange; individual producers’ filings would only cover their own operations. Official source: www.lme.com.

No SEC filer could be matched to “Aluminium market news data centre grid bess renewable energy demand” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Aluminium market data centre grid bess”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “aluminium” (search terms considered: aluminium, market, data, centre, grid, bess, renewable, energy).

Even the shorter phrase “Aluminium market data” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (aluminium, market, data, centre, grid, bess, renewable, energy) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 6 entities whose registered name contains the word “aluminium”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “aluminium” 6, “market” 458, “data” 483, “centre” 212, “grid” 74, “bess” 9. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: for recent news on “aluminium”, use the company’s own press releases or its home-exchange announcements, since there is no SEC 8-K feed for a non-filer. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Ambow education holding ltd. bullish and bearish analyst opinions

For “Ambow education holding ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Ambow Education Holding Ltd., which trades as AMBO and files under Central Index Key 1494558. EDGAR puts it in the “Services-Educational Services” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-14, across 301 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-13 by Ambow Education Holding Ltd. (CIK 1494558) — source document:

Ambow Education Holding Ltd. is not an operating company but a Cayman Islands holding company with operations primarily conducted by its subsidiaries in the U.S. Investors in our securities should be aware that they may never directly hold equity interests in our operating entities but rather are purchasing equity solely in Ambow Education Holding Ltd., our Cayman Islands holding company, which does not directly own substantially all of our business conducted by our U.S. subsidiaries. History and Development of the Company Our founder, Dr. Jin Huang, laid the foundation for Ambow in 2000. From its inception through January 2017, Ambow primarily operated in the Chinese market through a network of subsidiaries and Variable Interest Entities (VIEs).

Financial trend for Ambow Education Holding Ltd. from annual reports, periods 2019-12-31 to 2022-12-31: revenue went from 583,909,000 CNY (2019-12-31) to 102,352,000 CNY (2022-12-31), a change of -82.5%; net income (loss) went from -99,941,000 CNY (2019-12-31) to 3,002,000 CNY (2021-12-31), a change of +103.0%; total assets went from 1,020,799,000 CNY (2019-12-31) to 175,991,000 CNY (2022-12-31), a change of -82.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1494558, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Ambow Education Holding Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ambow Education Holding Ltd. (CIK 1494558) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-02-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 123 8-K or 6-K reports in Ambow Education Holding Ltd.’s recent EDGAR index, the 4 listed here run from 2026-05-28 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1494558 is on the EDGAR company page; the latest 10-K there is dated 2026-02-13 and the oldest filing in the recent index dates from 2010-07-14. Insider trades for Ambow Education Holding Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Amcon distributing company bullish and bearish analyst opinions

For “Amcon distributing company bullish and bearish analyst opinions”, the matching SEC registrant is AMCON DISTRIBUTING CO, which trades as DIT and files under Central Index Key 928465. EDGAR puts it in the “Wholesale-Groceries, General Line” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a CERT filed 2026-08-12, across 690 filings on record. This is reference material, not trading advice.

Financial trend for AMCON DISTRIBUTING CO from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from $16.67 million (2022-09-30) to $568,739 (2025-09-30), a change of -96.6%; total assets went from $289.12 million (2022-09-30) to $391.09 million (2025-09-30), a change of +35.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 928465, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AMCON DISTRIBUTING CO did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AMCON DISTRIBUTING CO (CIK 928465) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2025-11-07. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 174 8-K or 6-K reports in AMCON DISTRIBUTING CO’s recent EDGAR index, the 4 listed here run from 2026-02-10 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 690 recent EDGAR filings, AMCON DISTRIBUTING CO most often filed 4 (198), 8-K (174), 10-Q (91), SC 13G/A (51). A selection from 2026-01-20 to 2026-08-12:

The full record for CIK 928465 is on the EDGAR company page; the latest 10-K there is dated 2025-11-07 and the oldest filing in the recent index dates from 1996-08-13. Insider trades for AMCON DISTRIBUTING CO appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Amneal pharmaceuticals amrx news october 2026

For “Amneal pharmaceuticals amrx news october 2026”, the matching SEC registrant is Amneal Pharmaceuticals, Inc., which trades as AMRX and files under Central Index Key 1723128. EDGAR puts it in the “Pharmaceutical Preparations” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Atlas Holdings, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K/A filed 2026-10-23 (this view begins at filings dated on or before 2026-08-13), across 693 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-27 by Amneal Pharmaceuticals, Inc. (CIK 1723128) (passage 2, continuing from the earlier excerpt) — source document:

Immediately prior to the Reorganization (as defined herein), we held 50.4% of the Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held the remaining 49.6%. On November 7, 2023, we implemented a plan pursuant to which the Company and Amneal reorganized and simplified our corporate structure by eliminating our umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure whereby all stockholders hold their voting and economic interests directly through the public company (the “Reorganization”). Effective with the Reorganization, we hold 100% of the Amneal Common Units and continue to consolidate the financial statements of Amneal and its subsidiaries.

Financial trend for Amneal Pharmaceuticals, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.37 million (2025-09-30) to $57.66 million (2026-06-30), a change of +2334.0%; total assets went from $3.60 billion (2025-09-30) to $3.78 billion (2026-06-30), a change of +4.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1723128, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Amneal Pharmaceuticals, Inc. did not tag for that period.

Current reports. Of the 93 8-K or 6-K reports in Amneal Pharmaceuticals, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-27 to 2026-05-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1723128 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2017-11-21. One example from this record is the 4 filed 2026-09-02 (document). Insider trades for Amneal Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ana-001 clinical trial metavia

For “Ana-001 clinical trial metavia”, the matching SEC registrant is MetaVia Inc., which trades as MTVA and files under Central Index Key 1638287. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was NeuroBo Pharmaceuticals, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 631 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by MetaVia Inc. (CIK 1638287) — source document:

We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity. ● Vanoglipel (DA-1241) is a novel GPR119 (“GPR119”) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (“ T2DM”). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (“ GLP-1”), glucagon-dependent insulinotropic polypeptide receptor (“GIP”), and peptide YY (“PYY”) . These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel (DA-1241) has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies. o In Phase 1a and 1b human clinical trials, vanoglipel (DA-1241) was well tolerated in both healthy volunteers and those with T2DM. o We initiated a Phase 2a clinical trial in 2023 with the goal of establishing the mechanism of action and efficacy of vanoglipel (DA-1241) in the treatment of MASH and to evaluate trends for T2DM. This is the first-in-human MASH clinical trial for vanoglipel (DA-1241).

Financial trend for MetaVia Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$13.97 million (2022-12-31) to -$12.97 million (2025-12-31), a change of +7.1%; total assets went from $33.53 million (2022-12-31) to $11.12 million (2025-12-31), a change of -66.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1638287, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures MetaVia Inc. did not tag for that period.

MetaVia Inc. has 631 filings in its recent EDGAR index, including 10 annual reports and 31 quarterly reports; its newest filing is a 4 from 2026-10-13.

Current reports. Of the 182 8-K or 6-K reports in MetaVia Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-09 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1638287 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2015-04-08. Insider trades for MetaVia Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Anixa biosciences, inc. bullish and bearish analyst opinions

For “Anixa biosciences, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Anixa Biosciences Inc, which trades as ANIX and files under Central Index Key 715446. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was ITUS Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-22, across 981 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-01-12 by Anixa Biosciences Inc (CIK 715446) — source document:

Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology. Our therapeutics program consists of the development of liraltagene autoleucel (“lira-cel”), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”). Our vaccine programs include (i) the development of a vaccine against breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate.

Financial trend for Anixa Biosciences Inc from annual reports, periods 2022-10-31 to 2025-10-31: revenue went from $210,000 (2023-10-31) to $210,000 (2024-10-31), a change of +0.0%; net income (loss) went from -$13.60 million (2022-10-31) to -$10.93 million (2025-10-31), a change of +19.6%; total assets went from $30.41 million (2022-10-31) to $16.08 million (2025-10-31), a change of -47.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 715446, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Anixa Biosciences Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Anixa Biosciences Inc (CIK 715446) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-01-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 114 8-K or 6-K reports in Anixa Biosciences Inc’s recent EDGAR index, the 4 listed here run from 2025-03-21 to 2026-03-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 715446 is on the EDGAR company page; the latest 10-K there is dated 2026-01-12 and the oldest filing in the recent index dates from 1995-06-09. Insider trades for Anixa Biosciences Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aptevo therapeutics inc. bullish and bearish analyst opinions

For “Aptevo therapeutics inc. bullish and bearish analyst opinions”, the matching SEC registrant is Aptevo Therapeutics Inc., which trades as APVO and files under Central Index Key 1671584. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 736 filings on record. This is reference material, not trading advice.

Financial trend for Aptevo Therapeutics Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at $3.11 million; net income (loss) went from $8.03 million (2022-12-31) to -$25.97 million (2025-12-31), a change of -423.5%; total assets went from $34.22 million (2022-12-31) to $27.19 million (2025-12-31), a change of -20.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1671584, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Aptevo Therapeutics Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aptevo Therapeutics Inc. (CIK 1671584) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 165 8-K or 6-K reports in Aptevo Therapeutics Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-23 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 736 recent EDGAR filings, Aptevo Therapeutics Inc. most often filed 4 (233), 8-K (165), CORRESP (37), 10-Q (31). A selection from 2026-08-31 to 2026-09-25:

The full record for CIK 1671584 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2016-04-15. Insider trades for Aptevo Therapeutics Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Armada mercantile ltd. bullish and bearish analyst opinions

For “Armada mercantile ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Armada Mercantile Ltd, which trades as none listed and files under Central Index Key 1327899. EDGAR puts it in the “no SIC description” industry code with British Columbia, Canada as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D filed 2024-08-12, across 3 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Armada Mercantile Ltd (CIK 1327899) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Armada mercantile ltd. bullish and bearish analyst opinions”: Armada Mercantile Ltd’s EDGAR record from 2005-05-17 to 2024-08-12 consists only of Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading; REGDEX filings. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in British Columbia, Canada, its own reports would be with the Canadian Securities Administrators’ SEDAR+ system (www.sedarplus.ca).

Other filings. Across its 3 recent EDGAR filings, Armada Mercantile Ltd most often filed REGDEX (2), D (1). A selection from 2005-05-17 to 2024-08-12:

The full record for CIK 1327899 is on the EDGAR company page and the oldest filing in the recent index dates from 2005-05-17. Insider trades for Armada Mercantile Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Auna s.a. bullish and bearish analyst opinions

For “Auna s.a. bullish and bearish analyst opinions”, the matching SEC registrant is AUNA S.A., which trades as AUNA and files under Central Index Key 1799207. EDGAR puts it in the “Services-Offices & Clinics of Doctors of Medicine” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was AUNA S.A.A.. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-22, across 151 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-22 by AUNA S.A. (CIK 1799207) — source document:

Operating and Financial Review and Prospects 79 A. Operating Results 79 B. Liquidity and Capital Resources 95 C. Research and Development, Patents and Licenses, etc. 102 D. Trend Information 103 E. Critical Accounting Estimates 104 Item 6. Directors, Senior Management and Employees 106 A. Directors and Senior Management 106 B. Compensation of Directors and Executive Officers 109 C. Committees of the Board of Directors 110 D. Employees 110 E. Share Ownership 111 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 111 Item 7. Major Shareholders and Related Party Transactions 111 A. Major Shareholders 111 B. Related Party Transactions 113 C. Interests of Experts and Counsel 115 Item 8.

Financial trend for AUNA S.A. from annual reports, periods 2022-12-31 to 2024-12-31: revenue went from 2,451,608,000 PEN (2022-12-31) to 4,386,112,000 PEN (2024-12-31), a change of +78.9%; net income (loss) went from -76,830,000 PEN (2022-12-31) to 123,958,000 PEN (2024-12-31), a change of +261.3%; total assets went from 6,593,663,000 PEN (2022-12-31) to 7,080,720,000 PEN (2024-12-31), a change of +7.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1799207, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures AUNA S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AUNA S.A. (CIK 1799207) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 45 8-K or 6-K reports in AUNA S.A.’s recent EDGAR index, the 4 listed here run from 2026-07-07 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1799207 is on the EDGAR company page; the latest 20-F there is dated 2026-04-22 and the oldest filing in the recent index dates from 2020-06-18. Insider trades for AUNA S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Azitra, inc. bullish and bearish analyst opinions

For “Azitra, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Azitra, Inc., which trades as AZTR and files under Central Index Key 1701478. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Azitra Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 235 filings on record. This is reference material, not trading advice.

Financial trend for Azitra, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $284,000 (2022-12-31) to $0 (2025-12-31), a change of -100.0%; net income (loss) went from -$10.68 million (2022-12-31) to -$10.96 million (2025-12-31), a change of -2.6%; total assets went from $7.17 million (2022-12-31) to $5.03 million (2025-12-31), a change of -29.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1701478, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Azitra, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Azitra, Inc. (CIK 1701478) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 49 8-K or 6-K reports in Azitra, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-08 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 235 recent EDGAR filings, Azitra, Inc. most often filed 8-K (49), CORRESP (25), 4 (24), UPLOAD (12). A selection from 2026-06-25 to 2026-09-28:

The full record for CIK 1701478 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2017-03-20. Insider trades for Azitra, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Barings southeast self storage portfolio sec filing

What this search refers to. “Barings Southeast self storage portfolio” refers to a property portfolio rather than a registrant; Barings-managed vehicles such as Barings BDC and private funds file with the SEC, but individual property portfolios are reported only inside those vehicles’ filings or Form D notices. Official source: www.sec.gov.

No SEC filer could be matched to “Barings southeast self storage portfolio sec filing” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Barings southeast self storage portfolio sec”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “barings” (search terms considered: barings, southeast, self, storage, portfolio, sec, filing).

Even the shorter phrase “Barings southeast self” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (barings, southeast, self, storage, portfolio, sec, filing) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 195+ entities whose registered name contains the word “barings”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “barings” 233, “southeast” 219, “self” 495, “storage” 496, “portfolio” 473, “sec” 489. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: if “barings” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Bgsf, inc. bullish and bearish analyst opinions

For “Bgsf, inc. bullish and bearish analyst opinions”, the matching SEC registrant is BGSF, INC., which trades as BGSF and files under Central Index Key 1474903. EDGAR puts it in the “Services-Help Supply Services” industry code with DE as its state or country of incorporation; its earlier registered name was BG Staffing, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEFA14A filed 2026-09-16, across 602 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by BGSF, INC. (CIK 1474903) — source document:

We operate primarily within the U.S. through our Property Management segment, which provides maintenance and office field talent across 44 of the states and D.C. to property management companies responsible for the apartment communities and commercial buildings day to day operations. We provide field talent to a variety of client partners that are seeking to match their workforce requirements to their business needs. We employ a diverse operating model, both from a skill set and a geographic standpoint, which we believe mitigates downside revenue risk. Our workforce services consist of on-demand or short-term assignments and direct hire placements in the Property Management industry. Short-term workforce solutions assist employers in dealing with field talent demands caused by such factors as seasonality, fluctuations in client partner demand, vacations, illnesses, parental leave, and special projects without incurring the ongoing expense and administrative responsibilities associated with recruiting, hiring and retaining permanent field talent.

Financial trend for BGSF, INC. from annual reports, periods 2023-01-01 to 2025-12-28: revenue went from $298.42 million (2023-01-01) to $93.31 million (2025-12-28), a change of -68.7%; net income (loss) went from $25.36 million (2023-01-01) to -$11.43 million (2025-12-28), a change of -145.1%; total assets went from $194.67 million (2023-01-01) to $57.84 million (2025-12-28), a change of -70.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1474903, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BGSF, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BGSF, INC. (CIK 1474903) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 142 8-K or 6-K reports in BGSF, INC.’s recent EDGAR index, the 4 listed here run from 2026-03-11 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1474903 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2009-10-21. Insider trades for BGSF, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bioharvest sciences inc. bullish and bearish analyst opinions

For “Bioharvest sciences inc. bullish and bearish analyst opinions”, the matching SEC registrant is BIOHARVEST SCIENCES INC., which trades as BHST and files under Central Index Key 1723464. EDGAR puts it in the “Pharmaceutical Preparations” industry code with British Columbia, Canada as its state or country of incorporation; its earlier registered name was CANNA-V-CELL SCIENCES INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13, across 135 filings on record. This is reference material, not trading advice.

Financial trend for BIOHARVEST SCIENCES INC. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $12.67 million (2023-12-31) to $34.51 million (2025-12-31), a change of +172.3%; net income (loss) went from -$12.56 million (2023-12-31) to -$11.13 million (2025-12-31), a change of +11.4%; total assets went from $15.00 million (2023-12-31) to $47.66 million (2025-12-31), a change of +217.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1723464, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures BIOHARVEST SCIENCES INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BIOHARVEST SCIENCES INC. (CIK 1723464) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 40-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 92 8-K or 6-K reports in BIOHARVEST SCIENCES INC.’s recent EDGAR index, the 4 listed here run from 2026-09-15 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 135 recent EDGAR filings, BIOHARVEST SCIENCES INC. most often filed 6-K (92), D (13), UPLOAD (5), 424B7 (3). A selection from 2025-11-06 to 2026-03-31:

The full record for CIK 1723464 is on the EDGAR company page; the latest 40-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2017-11-24. Insider trades for BIOHARVEST SCIENCES INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bionexus gene lab corp. bullish and bearish analyst opinions

For “Bionexus gene lab corp. bullish and bearish analyst opinions”, the matching SEC registrant is BioNexus Gene Lab Corp, which trades as BGLC and files under Central Index Key 1737523. EDGAR puts it in the “Services-Medical Laboratories” industry code with WY as its state or country of incorporation; its earlier registered name was BioNexus Gene Lab Coporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-22, across 157 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-04-14 by BioNexus Gene Lab Corp (CIK 1737523) — source document:

BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (“Chemrex”) and MRNA Scientific Sdn. Bhd. (“MRNA Scientific”). Chemrex is engaged in the distribution of chemical raw materials, primarily for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. In November 2025, the Company entered into a Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform.

Financial trend for BioNexus Gene Lab Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $10.93 million (2022-12-31) to $7.42 million (2025-12-31), a change of -32.1%; net income (loss) went from -$355,966 (2022-12-31) to -$2.98 million (2025-12-31), a change of -738.5%; total assets went from $8.74 million (2022-12-31) to $9.25 million (2025-12-31), a change of +5.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1737523, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BioNexus Gene Lab Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BioNexus Gene Lab Corp (CIK 1737523) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 48 8-K or 6-K reports in BioNexus Gene Lab Corp’s recent EDGAR index, the 4 listed here run from 2026-03-17 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1737523 is on the EDGAR company page; the latest 10-K there is dated 2026-04-14 and the oldest filing in the recent index dates from 2019-01-29. Insider trades for BioNexus Gene Lab Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bitventures limited bullish and bearish analyst opinions

For “Bitventures limited bullish and bearish analyst opinions”, the matching SEC registrant is BitVentures Ltd, which trades as BVC and files under Central Index Key 1785680. EDGAR puts it in the “Investment Advice” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Santech Holdings Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 20-F filed 2026-10-16, across 102 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-10-16 by BitVentures Ltd (CIK 1785680) — source document:

We were incorporated in the Cayman Islands on July 19, 2019 as an exempted company with limited liability. Our principal executive offices are located at Level 15, AIA Central, No.1 Connaught Road Central, Central, Hong Kong. Our telephone number at this address is +852 2593 9309. Our registered office in the Cayman Islands is located at the offices of Portcullis (Cayman) Ltd, The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC on www.sec.gov.

Financial trend for BitVentures Ltd from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $15.26 million (2023-06-30) to $498,000 (2026-06-30), a change of -96.7%; net income (loss) was tagged only for 2023-06-30 at 129,881,000 CNY; total assets was tagged only for 2023-06-30 at 2,373,492,000 CNY. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1785680, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BitVentures Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BitVentures Ltd (CIK 1785680) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-10-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 45 8-K or 6-K reports in BitVentures Ltd’s recent EDGAR index, the 4 listed here run from 2026-01-02 to 2026-06-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1785680 is on the EDGAR company page; the latest 20-F there is dated 2026-10-16 and the oldest filing in the recent index dates from 2020-08-11. Insider trades for BitVentures Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Blossomhill therapeutics, inc. bullish and bearish analyst opinions

For “Blossomhill therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is BlossomHill Therapeutics, Inc., which trades as BLSM and files under Central Index Key 1839970. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-09-18, across 44 filings on record. This is reference material, not trading advice.

Financial trend for BlossomHill Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: net income (loss) went from -$13.24 million (2025-06-30) to -$23.76 million (2026-06-30), a change of -79.4%; total assets was tagged only for 2026-06-30 at $124.13 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1839970, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures BlossomHill Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BlossomHill Therapeutics, Inc. (CIK 1839970) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 3 8-K or 6-K reports in BlossomHill Therapeutics, Inc.’s recent EDGAR index, the 3 listed here run from 2026-08-10 to 2026-09-18, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 44 recent EDGAR filings, BlossomHill Therapeutics, Inc. most often filed 4 (11), 3 (11), D (4), 8-K (3). A selection from 2026-08-13 to 2026-09-18:

The full record for CIK 1839970 is on the EDGAR company page and the oldest filing in the recent index dates from 2021-01-11. Insider trades for BlossomHill Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bluejay diagnostics, inc. bullish and bearish analyst opinions

For “Bluejay diagnostics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Bluejay Diagnostics, Inc., which trades as BJDX and files under Central Index Key 1704287. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-13 (this view begins at filings dated on or before 2026-08-13), across 248 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Bluejay Diagnostics, Inc. (CIK 1704287) (passage 2, continuing from the earlier excerpt) — source document:

We are also working with Sanyoseiko to modify the manufacturing process of the Symphony cartridges to address certain technical issues to bring Symphony to a level consistent with necessary performance and quality requirements for regulatory submission. To achieve our plan, we expect to need to raise at least $20 million of further capital by the end of the 2027 fiscal year, which we hope to do in various tranches. Our Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP on the Symphony technology that we believe, if cleared, authorized, or approved by the FDA, could provide a solution to a significant market need in the United States.

Financial trend for Bluejay Diagnostics, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$1.60 million (2025-09-30) to -$2.32 million (2026-06-30), a change of -45.5%; total assets went from $4.89 million (2025-09-30) to $11.53 million (2026-06-30), a change of +135.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1704287, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Bluejay Diagnostics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bluejay Diagnostics, Inc. (CIK 1704287) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-05-07, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 67 8-K or 6-K reports in Bluejay Diagnostics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-02 to 2026-07-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1704287 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2017-04-19. One example from this record is the 4 filed 2026-08-18 (document). Insider trades for Bluejay Diagnostics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Blueport acquisition ltd bullish and bearish analyst opinions

For “Blueport acquisition ltd bullish and bearish analyst opinions”, the matching SEC registrant is Blueport Acquisition Ltd, which trades as BPAC, BPACR, BPACU and files under Central Index Key 2064177. EDGAR puts it in the “Blank Checks” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-06, across 47 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by Blueport Acquisition Ltd (CIK 2064177) — source document:

Blueport Acquisition Ltd (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on January 13, 2025. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. Initial Public Offering and Private Placement The registration statement for the Company’s initial public offering (“IPO”) became effective on November 10, 2025.

Financial trend for Blueport Acquisition Ltd from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$33,070 (2025-09-30) to $87,581 (2026-06-30), a change of +364.8%; total assets went from $182,701 (2025-09-30) to $58.92 million (2026-06-30), a change of +32147.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2064177, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Blueport Acquisition Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Blueport Acquisition Ltd (CIK 2064177) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Blueport Acquisition Ltd — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-05-04.

Current reports. Of the 5 8-K or 6-K reports in Blueport Acquisition Ltd’s recent EDGAR index, the 4 listed here run from 2025-11-19 to 2026-05-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2064177 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2025-04-09. Insider trades for Blueport Acquisition Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Braskem bonds

For “Braskem bonds”, the matching SEC registrant is BRASKEM SA, which trades as BAK and files under Central Index Key 1071438. EDGAR puts it in the “Industrial Organic Chemicals” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was BRASKEM SA. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-22, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-20 by BRASKEM SA (CIK 1071438) — source document:

We are a corporation ( sociedade por ações ) organized under the laws of Brazil. Our registered office is at Rua Eteno, 1561, Pólo Petroquímico, Camaçari, Bahia, postal code 42810-000, Brazil, and our telephone number at this address is +55 71 3413-2102. Our head office is at Rua Lemos Monteiro, 120 – 24 º floor, Butantã, São Paulo, SP, postal code 05501-050, Brazil, and our telephone number at this address is +55 11 3576-9000. We are the largest producer of plastics in the Americas, based on the annual production capacity of our plants, according to CMA. We operate in the first and second generations of the petrochemical industry, with integrated operations in Brazil and Mexico.

Financial trend for BRASKEM SA from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 105,625,000,000 BRL (2021-12-31) to 77,411,000,000 BRL (2024-12-31), a change of -26.7%; net income (loss) went from 13,962,000,000 BRL (2021-12-31) to -12,052,000,000 BRL (2024-12-31), a change of -186.3%; total assets went from 92,564,368,000 BRL (2021-12-31) to 101,575,000,000 BRL (2024-12-31), a change of +9.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1071438, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures BRASKEM SA did not tag for that period.

BRASKEM SA has 1000 filings in its recent EDGAR index, including 6 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-22.

Current reports. Of the 891 8-K or 6-K reports in BRASKEM SA’s recent EDGAR index, the 4 listed here run from 2026-10-13 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1071438 is on the EDGAR company page; the latest 20-F there is dated 2026-04-20 and the oldest filing in the recent index dates from 2020-07-14. Insider trades for BRASKEM SA appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Braveheart bio, inc. bullish and bearish analyst opinions

For “Braveheart bio, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Braveheart Bio, Inc., which trades as BRVE and files under Central Index Key 2131524. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13D/A filed 2026-09-10, across 46 filings on record. This is reference material, not trading advice.

Financial trend for Braveheart Bio, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: net income (loss) went from -$381,000 (2025-06-30) to -$14.99 million (2026-06-30), a change of -3833.9%; total assets was tagged only for 2026-06-30 at $126.96 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2131524, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Braveheart Bio, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Braveheart Bio, Inc. (CIK 2131524) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-08. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 2 8-K or 6-K reports in Braveheart Bio, Inc.’s recent EDGAR index, the 2 listed here run from 2026-08-07 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 46 recent EDGAR filings, Braveheart Bio, Inc. most often filed 3 (15), 4 (14), 8-K (2), SCHEDULE 13D (2). A selection from 2026-08-14 to 2026-09-10:

The full record for CIK 2131524 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-04-29. Insider trades for Braveheart Bio, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Brc group holdings

For “Brc group holdings”, the matching SEC registrant is BRC Group Holdings, Inc., which trades as RILY, RILYG, RILYL, RILYP, RILYT, RILYZ and files under Central Index Key 1464790. EDGAR puts it in the “Investment Advice” industry code with DE as its state or country of incorporation; its earlier registered name was BRC Group Holdings, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-01, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by BRC Group Holdings, Inc. (CIK 1464790) — source document:

BRC Group Holdings, Inc. (Nasdaq: RILY) (the “Company” or “BRCGH”), which changed its name from B. Riley Financial, Inc. effective January 1, 2026, is a diversified holding company offering a platform of businesses, including financial services (with complementary banking and wealth management businesses), telecom, retail, and investments in equity, debt and venture capital. We refer to BRCGH as having a “platform” because of the unique composition of our financial services businesses and diversification of its operations. Our core financial services platform provides small cap and middle market companies customized end-to-end solutions at every stage of the enterprise life cycle. Our complementary banking business offers comprehensive services in capital markets, sales, trading, research, merchant banking, M&A, and restructuring.

Financial trend for BRC Group Holdings, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $939.48 million (2022-12-31) to $967.60 million (2025-12-31), a change of +3.0%; net income (loss) went from -$159.83 million (2022-12-31) to $307.42 million (2025-12-31), a change of +292.3%; total assets went from $6.11 billion (2022-12-31) to $1.71 billion (2025-12-31), a change of -72.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1464790, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BRC Group Holdings, Inc. did not tag for that period.

BRC Group Holdings, Inc. has 1002 filings in its recent EDGAR index, including 7 annual reports and 21 quarterly reports; its newest filing is a 8-K from 2026-10-01.

Current reports. Of the 136 8-K or 6-K reports in BRC Group Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1464790 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-01 and the oldest filing in the recent index dates from 2019-11-01. Insider trades for BRC Group Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Carlsmed, inc. bullish and bearish analyst opinions

For “Carlsmed, inc. bullish and bearish analyst opinions”, the matching SEC registrant is CARLSMED, INC., which trades as CARL and files under Central Index Key 1794546. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-14, across 93 filings on record. This is reference material, not trading advice.

Financial trend for CARLSMED, INC. from annual reports, periods 2024-12-31 to 2025-12-31: revenue went from $27.16 million (2024-12-31) to $50.51 million (2025-12-31), a change of +85.9%; net income (loss) went from -$24.26 million (2024-12-31) to -$29.63 million (2025-12-31), a change of -22.2%; total assets went from $51.82 million (2024-12-31) to $130.12 million (2025-12-31), a change of +151.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1794546, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 2 periods shown, dashes mark figures CARLSMED, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CARLSMED, INC. (CIK 1794546) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 11 8-K or 6-K reports in CARLSMED, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 93 recent EDGAR filings, CARLSMED, INC. most often filed 4 (24), 3 (14), 8-K (11), CORRESP (5). A selection from 2026-10-01 to 2026-10-14:

The full record for CIK 1794546 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2019-11-19. Insider trades for CARLSMED, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cbrands international mobile apps

Because this search is about mobile apps from Cbrands international, the record that answers it is the developer listing in the app stores. Check Google Play (Developer field) and the App Store (Seller field): a match to the company’s legal name, plus a privacy policy hosted on its own domain, is what confirms an app is genuinely the company’s.

No SEC filer could be matched to “Cbrands international mobile apps” with a single, clear Central Index Key: the phrase “Cbrands international” appears in 2 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cbrands” (search terms considered: cbrands, international).

In the 2 most relevant full-text hits returned for “Cbrands international”, filings range from 2025-04-23 to 2026-04-22. The filers whose documents mention it most often are CONSTELLATION BRANDS, INC. (STZ) (CIK 0000016918) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “cbrands”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cbrands” 0, “international” 458. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “international”: 12 TELECOM INTERNATIONAL INC (CIK 1433865), 1607 CAPITAL INTERNATIONAL EQUITY FUND LP (CIK 1426153), 1992 MSF INTERNATIONAL LTD. (CIK 1308315). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

Updated Oct 25, 2026 ET

Celcuity

For “Celcuity”, the matching SEC registrant is Celcuity Inc., which trades as CELC and files under Central Index Key 1603454. EDGAR puts it in the “Services-Medical Laboratories” industry code with DE as its state or country of incorporation; its earlier registered name was Celcuity LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-09, across 540 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Celcuity Inc. (CIK 1603454) — source document:

Unless otherwise provided in this Annual Report, references to the “Company,” “we,” “us,” and “our” and similar references refer to Celcuity Inc., a Delaware corporation. We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks, trade names and service marks in this Annual Report, including those owned by third parties, may be referred to without the ® , TM or SM symbols, but such references should not be construed as any indicator that the owner of such trademarks, trade names and service marks will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks, trade names and service marks to imply an endorsement or sponsorship of us by any other companies.

Financial trend for Celcuity Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$40.37 million (2022-12-31) to -$177.04 million (2025-12-31), a change of -338.5%; total assets went from $175.70 million (2022-12-31) to $466.56 million (2025-12-31), a change of +165.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1603454, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Celcuity Inc. did not tag for that period.

Celcuity Inc. has 540 filings in its recent EDGAR index, including 9 annual reports and 27 quarterly reports; its newest filing is a 4 from 2026-10-09.

Current reports. Of the 89 8-K or 6-K reports in Celcuity Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1603454 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2014-03-24. Insider trades for Celcuity Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cellectis s.a. bullish and bearish analyst opinions

For “Cellectis s.a. bullish and bearish analyst opinions”, the matching SEC registrant is Cellectis S.A., which trades as CLLS and files under Central Index Key 1627281. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with France as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-09-14, across 533 filings on record. This is reference material, not trading advice.

Financial trend for Cellectis S.A. from annual reports, periods 2023-09-30 to 2025-12-31: revenue went from $755,000 (2023-12-31) to $72.95 million (2025-12-31), a change of +9562.1%; net income (loss) went from -$108.44 million (2023-12-31) to -$67.59 million (2025-12-31), a change of +37.7%; total assets went from $209.70 million (2023-09-30) to $324.72 million (2025-12-31), a change of +54.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1627281, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Cellectis S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cellectis S.A. (CIK 1627281) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 387 8-K or 6-K reports in Cellectis S.A.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 533 recent EDGAR filings, Cellectis S.A. most often filed 6-K (387), SC 13G/A (16), SC 13D/A (12), 20-F (11). A selection from 2025-12-12 to 2026-09-11:

The full record for CIK 1627281 is on the EDGAR company page; the latest 20-F there is dated 2026-03-20 and the oldest filing in the recent index dates from 2014-12-19. Insider trades for Cellectis S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET